Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Sökning: WFRF:(Lazarus Hillard M.) > Reduced-Intensity A...

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors

Klyuchnikov, Evgeny (författare): Univ Canc Ctr Hamburg, Dept Stem Cell Transplantat, Hamburg, Germany.

Bacher, Ulrike (författare): Univ Gottingen, Dept Hematol & Internal Oncol, D-37073 Gottingen, Germany.

Kroeger, Nicolaus M. (författare): Univ Canc Ctr Hamburg, Dept Stem Cell Transplantat, Hamburg, Germany.

visa fler...

Hari, Parameswaran N. (författare): Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.

Ahn, Kwang Woo (författare): Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA.

Carreras, Jeanette (författare): Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.

Bachanova, Veronika (författare): Univ Minnesota, Med Ctr, Bone & Marrow Transplant Program, Minneapolis, MN 55455 USA.

Bashey, Asad (författare): Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA.

Cohen, Jonathon B. (författare): Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA.

D'Souza, Anita (författare): Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.

Freytes, Cesar O. (författare): South Texas Vet Hlth Care Syst, San Antonio, TX USA.;Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.;Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Expt Med, Hematol Res Ctr, London, England.

Gale, Robert Peter (författare)

Ganguly, Siddhartha (författare): Univ Kansas, Med Ctr, Blood & Marrow Transplantat, Div Hematol & Oncol, Kansas City, KS 66103 USA.

Hertzberg, Mark S. (författare): Prince Wales Hosp, Dept Haematol, Randwick, NSW 2031, Australia.

Holmberg, Leona A. (författare): Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.

Kharfan-Dabaja, Mohamed A. (författare): H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA.

Klein, Andreas (författare): Tufts Med Ctr, Div Hematol Oncol, Dept Med, Boston, MA USA.

Ku, Grace H. (författare): Univ Calif San Diego, Dept Med, Div Blood & Marrow Transplantat, San Diego, CA 92103 USA.

Laport, Ginna G. (författare): Stanford Hosp & Clin, Div Bone Marrow Transplantat, Stanford, CA USA.

Lazarus, Hillard M. (författare): Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA.

Miller, Alan M. (författare): Baylor Univ, Med Ctr, Dept Oncol, Dallas, TX USA.

Mussetti, Alberto (författare): Fdn IRCCS Ist Nazl Tumori, SC Ematol & Trapianto Midollo Osseo, Milan, Italy.;Univ Milan, Milan, Italy.

Olsson, Richard F. (författare): Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Div Therapeut Immunol, Dept Lab Med, Stockholm, Sweden.

Slavin, Shimon (författare): Int Ctr Cell Therapy & Canc Immunotherapy, Tel Aviv, Israel.

Usmani, Saad Z. (författare): Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol, Med Oncol, Charlotte, NC USA.

Vij, Ravi (författare): Washington Univ, Sch Med, Div Hematol & Oncol, St Louis, MO USA.

Wood, William A. (författare): Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC USA.

Maloney, David G. (författare): Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.

Sureda, Anna M. (författare): Hosp Duran & Reynals, Inst Catala Oncol, Serv Hematol, Barcelona, Spain.;European Grp Blood & Marrow Transplantat, Milan, Italy.

Smith, Sonali M. (författare): Univ Chicago, Sect Hematol Oncol, Chicago, IL 60637 USA.

Hamadani, Mehdi (författare): Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.

visa färre...

Univ Canc Ctr Hamburg, Dept Stem Cell Transplantat, Hamburg, Germany Univ Gottingen, Dept Hematol & Internal Oncol, D-37073 Gottingen, Germany. (creator_code:org_t)

Elsevier BV, 2015
2015
Engelska.
Ingår i: Biology of blood and marrow transplantation. - : Elsevier BV. - 1083-8791 .- 1523-6536. ; 21:12, s. 2091-2099

Relaterad länk:: http://www.bbmt.org/...; visa fler...; https://urn.kb.se/re...; https://doi.org/10.1...; http://kipublication...; visa färre...

Tidskriftsartikel (refereegranskat)

Abstract Ämnesord

Stäng

This study was conducted to compare long-term outcomes in patients with refractory/relapsed grades 1 and 2 follicular lymphoma (FL) after allogeneic (allo) versus autologous (auto) hematopoietic cell transplantation (HCT) in the rituximab era. Adult patients with relapsed/refractory grades 1 and 2 FL undergoing first reduced-intensity allo-HCT or first autograft during 2000 to 2012 were evaluated. A total of 518 rituximab-treated patients were included. Allo-HCT patients were younger and more heavily pretreated, and more patients had advanced stage and chemoresistant disease. The 5-year adjusted probabilities, comparing auto-HCT versus allo-HCT groups for nonrelapse mortality (NRM) were 5% versus 26% (P <.0001); relapse/progression: 54% versus 20% (P <.0001); progression-free survival (PFS): 41% versus 58% (P <.001), and overall survival (OS): 74% versus 66% (P =.05). Auto-HCT was associated with a higher risk of relapse/progression beyond 5 months after HCT (relative risk [RR], 4.4; P <.0001) and worse PFS (RR, 2.9; P <.0001) beyond 11 months after HCT. In the first 24 months after HO', auto-HCT was associated with improved OS (RR,.41; P <.0001), but beyond 24 months, it was associated with inferior OS (RR, 2.2; P =.006). A landmark analysis of patients alive and progression-free at 2 years after HO' confirmed these observations, showing no difference in further NRM between both groups, but there was significantly higher risk of relapse/progression (RR, 7.3; P <.0001) and inferior PFS (RR, 3.2; P <.0001) and OS (RR, 2.1; P =.04) after auto-HCT. The 10-year cumulative incidences of second hematological malignancies after allo-HCT and auto-HCT were 0% and 7%, respectively. Auto-HCT and reduced-intensity conditioned allo-HCT as first transplantation approach can provide durable disease control in grades 1 and 2 FL patients. Continued disease relapse risk after auto-HCT translates into improved PFS and OS after allo-HCT in long-term survivors.

Hitta via bibliotek

Biology of blood and marrow transplantation (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Hematologi

Artiklar i publikationen: Biology of blood ...

Av lärosätet: Uppsala universitet; Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors

Ämnesord

Nyckelord

Publikations- och innehållstyp

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Sök utanför SwePub